123 related articles for article (PubMed ID: 35315510)
1. A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
Chen X; Huang J; Xu N; Fan Z; Nie D; Huang F; Sun Q; Zhang X; Liang X; Shi P; Wang Z; Liu H; Xu J; Dai M; Yu G; Zhang Y; Sun J; Liu Q; Xuan L
Cancer; 2022 Jun; 128(11):2138-2147. PubMed ID: 35315510
[TBL] [Abstract][Full Text] [Related]
2. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia].
Jin XS; Yang L; Wang BH; Li HH; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1675-1682. PubMed ID: 28024476
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value and Prognosis Significance of Cerebrospinal Fluid Examination by Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.
Xue L; Shang Q; Lu A; Zuo Y; Ding M; Zhang L; Jia Y
Technol Cancer Res Treat; 2023; 22():15330338231181025. PubMed ID: 37350078
[No Abstract] [Full Text] [Related]
6. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy.
Khimani NB; Ng AK; Chen YH; Catalano P; Silver B; Mauch PM
Ann Oncol; 2011 Apr; 22(4):979-984. PubMed ID: 20935059
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
8. [The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia].
Fei XH; Gu JY; Yin YM; Cheng HY; Zhang WJ; Zhang SQ; Zhao J; Wang JB
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):578-583. PubMed ID: 32397021
[No Abstract] [Full Text] [Related]
9. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
10. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
Moiseev I; Bondarenko S; Morozova E; Vlasova Y; Dotsenko A; Epifanovskaya O; Babenko E; Botina A; Baykov V; Surkova E; Lapin S; Beynarovich A; Borzenkova E; Golosgchapov O; Kanunnikov M; Kudyasheva O; Ovechkina V; Pirogova O; Porunova V; Rudakova T; Smikova O; Smirnova A; Afansyev B
Transplant Cell Ther; 2021 Jul; 27(7):601.e1-601.e7. PubMed ID: 33845259
[TBL] [Abstract][Full Text] [Related]
12. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.
Si MY; Fan ZC; Li YZ; Chang XL; Xie QD; Jiao XY
J Neurooncol; 2015 Apr; 122(2):229-44. PubMed ID: 25630624
[TBL] [Abstract][Full Text] [Related]
14. [Expression of osteopontin in central nervous system leukemia and its clinical significance].
Fang XM; Pan XH; Chen M; Zeng WW; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):325-8. PubMed ID: 23628025
[TBL] [Abstract][Full Text] [Related]
15. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
16. Obesity as the initial manifestation of central nervous system relapse of acute lymphoblastic leukemia: case report and literature review.
Zhang LD; Li YH; Ke ZY; Huang LB; Luo XQ
J Cancer Res Ther; 2012; 8(1):151-3. PubMed ID: 22531539
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
Dietrich J; Versmee L; Drappatz J; Eichler AF; Nayak L; Norden A; Wong E; Pisapia MR; Jones SS; Gordon AB; Chabner BA; Hochberg F; Batchelor TT
Oncologist; 2020 Sep; 25(9):747-e1273. PubMed ID: 32520407
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of cerebrospinal fluid hydrogen sulfide in central nervous system leukemia.
DU SX; Xiao J; Guan F; Sun LM; Wu WS; Tang H; DU JB; Tang CS; Jin HF
Chin Med J (Engl); 2011 Nov; 124(21):3450-4. PubMed ID: 22340157
[TBL] [Abstract][Full Text] [Related]
19. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
20. Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
Zhou H; Zheng C; Zhu X; Tang B; Tong J; Zhang X; Zhang L; Liu H; Sun Z
Pediatr Transplant; 2016 Dec; 20(8):1117-1124. PubMed ID: 27620713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
